Prescription medication · Combined Oral Contraceptive
drospirenone/ethinyl estradiol
Also sold as Yaz, Yasmin. This medicine can prevent pregnancy.
Data updated 2026-05-15
- 72,136
- FDA reports
- 30
- InteractionsSeveral interactions
- $4.40
- Brand price (NADAC)
What the data shows
drospirenone/ethinyl estradiol (Yaz) is a prescription Combined Oral Contraceptive, with 72,136 FDA adverse-event reports on file, with 30 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
drospirenone/ethinyl estradiol (Yaz) is a prescription Combined Oral Contraceptive. This medicine can prevent pregnancy.
This medicine contains drospirenone and ethinyl estradiol, which are hormones that prevent pregnancy. It also contains folate to help raise folate levels.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$4.40/unit
Generic Available
No
BAYER HLTHCARE
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
This medicine can prevent pregnancy.
Common side effects
Headache or migraine, Irregular periods, Nausea or vomiting
Key warnings
Cigarette smoking increases your risk of serious heart problems when using birth control pills.
The sections below are summarized in plain English from drospirenone/ethinyl estradiol's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
This medicine prevents pregnancy by stopping ovulation (the release of an egg from the ovary). It also changes the lining of the uterus, making it harder for a fertilized egg to implant. The folate helps increase folate levels in the body.
Side Effects (from patient reports)
Based on 72,136 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for drospirenone/ethinyl estradiol, by number of reports
- Pain
Pain
13,037 reports
- Injury
Injury
10,860 reports
- Blood clot in the lungs
Blood clot in the lungs
9,316 reports
- Blood clot in a deep vein
Blood clot in a deep vein
8,390 reports
- Anxiety
Anxiety
6,996 reports
- Emotional distress
Emotional distress
6,439 reports
- Long-term gallbladder inflammation
Long-term gallbladder inflammation
5,568 reports
- Gallstones 4,132
Gallstones
4,132 reports
- Gallbladder problem 4,073
Gallbladder problem
4,073 reports
- Decline in general health 3,325
Decline in general health
3,325 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Serious Warnings
Cigarette smoking increases your risk of serious heart problems when using birth control pills. This risk is higher if you are over 35 and smoke. Women over 35 who smoke should not use this medicine.
Known Drug Interactions
Potential to Increase Serum Potassium Concentration There is a potential for an increase in serum potassium concentration in women taking drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets with other drugs that may increase serum potassium concentration [see Warnings And Precautions ( 5.2 ) and And Clinical Pharmacology ( 12.3 )]. 7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets with HCV drug...
Mechanism: Drospirenone can cause your body to keep too much potassium, and taking it with other similar drugs can make this effect stronger.
Substances Increasing the Plasma Concentrations of COCs Co-administration of atorvastatin and certain COCs containing EE increase AUC values for EE by approximately 20%.
Mechanism: Taking atorvastatin can cause the level of estrogen from your birth control pill to increase in your body.
COCs Increasing the Plasma Concentrations of CYP450 Enzymes In clinical studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase.
Mechanism: The birth control pill slows down how your body breaks down omeprazole. This can cause the level of omeprazole in your blood to rise slightly.
COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary.
Mechanism: The birth control pill makes your body get rid of lamotrigine much faster than usual. This can lower the amount of medicine in your blood and make it less effective at preventing seizures.
Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St.
Mechanism: Topiramate causes your body to process birth control hormones faster than normal. This can make the birth control pill less effective at preventing pregnancy.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if I experience severe abdominal pain?
Can this medication be used to treat premenstrual syndrome (PMS)?
Will this medication protect me from sexually transmitted infections (STIs)?
Can I take this medication if I have high blood pressure?
What if I have a headache with vision changes?
Can I take this with St. John's Wort?
What do the different colored pills mean?
Can this medicine affect my weight?
What if I start spotting between periods?
Is it okay to drink grapefruit juice while taking this?
What are the common side effects of drospirenone/ethinyl estradiol?
Does drospirenone/ethinyl estradiol interact with other medications?
What drug class is drospirenone/ethinyl estradiol?
What pregnancy or breastfeeding source fields are listed for drospirenone/ethinyl estradiol?
Related Medications in Combined Oral Contraceptive
Other drugs grouped near drospirenone/ethinyl estradiol - same-class peers and common alternatives.
abiraterone
Zytiga
Abiraterone (Zytiga) is a medicine used with prednisone to treat prostate cancer that has spread.
Compare with drospirenone/ethinyl estradiol →
anastrozole
Arimidex
Anastrozole is a medicine used to treat breast cancer in women after menopause.
Compare with drospirenone/ethinyl estradiol →
bazedoxifene/conjugated estrogens
Duavee
Duavee is a combination medicine containing estrogen and a drug that blocks estrogen in some parts of the body.
Compare with drospirenone/ethinyl estradiol →
cabergoline
Dostinex
Cabergoline is a medicine that helps lower the amount of prolactin in your body.
Compare with drospirenone/ethinyl estradiol →
clomiphene
Clomid, Serophene
Clomiphene citrate is a medicine that helps women ovulate.
Compare with drospirenone/ethinyl estradiol →
Compare drospirenone/ethinyl estradiol vs abiraterone side-by-side →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on drospirenone/ethinyl estradiol
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for drospirenone/ethinyl estradiol
The FDA label for drospirenone/ethinyl estradiol (sold under brand names such as Yaz, Yasmin) classifies it as a prescription-only medication in the Combined Oral Contraceptive class. This medicine can prevent pregnancy. Official labeling lists 4 commonly reported side effects, including Headache or migraine, Irregular periods, Nausea or vomiting.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 72,136 voluntary reports. The database also lists 30 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: December 8, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages